FR09C0037I1 - - Google Patents

Info

Publication number
FR09C0037I1
FR09C0037I1 FR09C0037C FR09C0037I1 FR 09C0037 I1 FR09C0037 I1 FR 09C0037I1 FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 I1 FR09C0037 I1 FR 09C0037I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR09C0037I1 publication Critical patent/FR09C0037I1/fr
Application granted granted Critical
Publication of FR09C0037I2 publication Critical patent/FR09C0037I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR09C0037C 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise Active FR09C0037I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042001 1997-08-28
KR19970042002 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (fr) 1997-08-28 1998-08-25 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Publications (2)

Publication Number Publication Date
FR09C0037I1 true FR09C0037I1 (fr) 2009-09-25
FR09C0037I2 FR09C0037I2 (fr) 2021-11-05

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0037C Active FR09C0037I2 (fr) 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Country Status (15)

Country Link
US (1) US6309650B1 (fr)
EP (2) EP1025209B1 (fr)
JP (1) JP4161017B2 (fr)
KR (1) KR100314404B1 (fr)
CN (1) CN1142271C (fr)
AU (1) AU748730B2 (fr)
CA (1) CA2301000C (fr)
DE (2) DE122009000037I2 (fr)
DK (2) DK1604685T3 (fr)
ES (2) ES2382946T3 (fr)
FR (1) FR09C0037I2 (fr)
MY (1) MY129773A (fr)
NL (1) NL300391I2 (fr)
NZ (1) NZ503522A (fr)
WO (1) WO1999011762A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
AU743546B2 (en) 1998-10-05 2002-01-31 Research Foundation For Microbial Diseases Of Osaka University, The Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
CA2650236C (fr) * 1999-04-22 2016-01-12 United States Of America, As Represented By The Secretary Of Agriculture Vaccin contre le syndrome dysgenesique respiratoire porcin base sur l'isolat ja-142
JP4751558B2 (ja) * 2000-04-07 2011-08-17 一般財団法人化学及血清療法研究所 日本脳炎不活化ワクチン及びその製造方法
BR0210628A (pt) * 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
WO2005080556A2 (fr) * 2004-02-23 2005-09-01 Crucell Holland B.V. Procedes de purification de virus
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
WO2006108707A1 (fr) * 2005-04-11 2006-10-19 Crucell Holland B.V. Purification de virus faisant appel a une ultrafiltration
CA2676775A1 (fr) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Vecteur vaccinal flavivirus contre le virus de la grippe
KR20160003301A (ko) * 2007-12-26 2016-01-08 기타사토 다이이치 산쿄 백신 가부시키가이샤 안정하게 장기간 보존할 수 있는 일본뇌염 백신의 제조방법 및 그 백신의 용도
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
JP5744517B2 (ja) * 2008-07-30 2015-07-08 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
WO2010137036A2 (fr) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Nouveau vaccin contre l'encéphalite japonaise et procédé de fabrication correspondant
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
PT3269386T (pt) 2011-12-06 2022-12-05 Valneva Austria Gmbh Compostos de alumínio para utilização em terapêuticas e vacinas
CN105744952A (zh) * 2013-09-14 2016-07-06 巴拉特生物技术国际有限公司 病毒疫苗及其制备方法
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP4253403A3 (fr) 2015-12-23 2023-12-27 Valneva Austria GmbH Procédé de purification du virus zika
KR102405736B1 (ko) * 2016-01-15 2022-06-07 케이엠 바이올로직스 가부시키가이샤 고정화 바이러스 입자를 포함하는 백신
WO2017210215A1 (fr) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Vaccin contre le virus zika et procédés d'utilisation
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法
CA3081578A1 (fr) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Vaccins et compositions immunogenes anti-zika, et leurs procedes d'utilisation
BR112020010466A2 (pt) 2017-11-30 2020-11-24 Takeda Vaccines, Inc. composições imunogênicas e vacinas contra zika, métodos de uso das mesmas
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
EP3845639A4 (fr) * 2018-08-27 2022-05-11 Mican Technologies Inc. Procédé d'évaluation de médicaments anti-infectieux, vaccins, etc. utilisation de cellules monocytaires immortalisées et de cellules induites
EP3895729A1 (fr) 2020-03-01 2021-10-20 Valneva Austria GmbH Vaccin contre le virus sars-cov-2 adjuvé par cpg
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＣｐＧアジュバント化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
WO2021204825A2 (fr) 2020-04-06 2021-10-14 Valneva Austria Gmbh Vaccin à virus sars-cov-2 inactivé
WO2023148256A1 (fr) 2022-02-02 2023-08-10 Valneva Austria Gmbh Vaccin à virus sars-cov-2 inactivé
WO2024153686A1 (fr) 2023-01-18 2024-07-25 Valneva Austria Gmbh Procédé de production de virus dans un bioréacteur

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (fr) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Vaccin vivant contre les infections à virus getah, et vaccin vivant trivalent contre le virus de l'encéphalite japonaise, le parvovirus porcin et le virus getah
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
NL300391I2 (nl) 2009-11-02
DE122009000037I2 (de) 2011-06-16
JP4161017B2 (ja) 2008-10-08
ES2281929T3 (es) 2007-10-01
WO1999011762A1 (fr) 1999-03-11
KR100314404B1 (ko) 2002-10-12
NL300391I1 (nl) 2009-08-03
DE69837211T2 (de) 2007-12-06
CA2301000C (fr) 2003-07-08
DE122009000037I1 (de) 2009-11-05
MY129773A (en) 2007-04-30
DK1025209T3 (da) 2007-06-25
EP1604685A3 (fr) 2006-07-05
NZ503522A (en) 2001-06-29
DE69837211D1 (de) 2007-04-12
US6309650B1 (en) 2001-10-30
CN1272879A (zh) 2000-11-08
KR19990023955A (ko) 1999-03-25
EP1025209B1 (fr) 2007-02-28
EP1604685A2 (fr) 2005-12-14
CN1142271C (zh) 2004-03-17
ES2382946T3 (es) 2012-06-14
CA2301000A1 (fr) 1999-03-11
EP1025209A1 (fr) 2000-08-09
FR09C0037I2 (fr) 2021-11-05
AU748730B2 (en) 2002-06-13
AU9004798A (en) 1999-03-22
JP2001514844A (ja) 2001-09-18
DK1604685T3 (da) 2012-06-18
EP1604685B1 (fr) 2012-02-22

Similar Documents

Publication Publication Date Title
BE2018C032I2 (fr)
FR07C0057I1 (fr)
CH0944937H2 (fr)
BR9701757A (fr)
BR9700653A (fr)
CN3058025S (fr)
BY4238C1 (fr)
BY4349C1 (fr)
CN3053170S (fr)
CN3053500S (fr)
CN3054099S (fr)
CN3054162S (fr)
CN3054556S (fr)
CN3054902S (fr)
CN3055123S (fr)
CN3055179S (fr)
CN3055389S (fr)
CN3055519S (fr)
CN3055603S (fr)
CN3055713S (fr)
CN3056209S (fr)
CN3056251S (fr)
CN3056276S (fr)
CN3056417S (fr)
CN3056418S (fr)